文献速递前列腺增生与排尿功能障碍

锯叶棕己烷提取物治疗良性前列腺增生相关下尿路症状的疗效与安全性:随机对照试验与观察性研究的系统评价与荟萃分析

Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
PubMed 文献 · BJU Int · 2018-06-06

结果显示,与安慰剂相比,HESr减少夜尿次数并改善最大尿流率(Qmax);与α受体阻滞剂相比,国际前列腺症状评分(IPSS)和Qmax改善相似;总体安全性良好。

要点

  • 与安慰剂相比,HESr每晚减少0.64次排尿并提高Qmax 2.75 mL/s。
  • 与坦索罗辛相比,HESr在IPSS和Qmax改善上效果相似。
  • HESr总体耐受性良好,胃肠道不良反应最常见(平均发生率3.8%)。

核心结论

  • HESr(Permixon)与安慰剂相比可减少夜尿并改善Qmax,缓解LUTS的疗效与坦索罗辛及短期5α还原酶抑制剂相似。
  • HESr(Permixon)似乎是长期药物治疗LUTS/BPH的有效且耐受性良好的选择。

研究设计与样本

  • 系统评价与荟萃分析,纳入随机对照试验和前瞻性观察性研究。
  • 检索Medline、Web of Knowledge、Scopus、Cochrane Library及参考文献,截至2017年3月。
  • 仅纳入研究Permixon的研究,排除研究其他锯叶棕提取物的文章。
  • 采用随机效应模型汇总分析,并对治疗≥1年的研究进行亚组分析。

主要发现

  • 与安慰剂相比,HESr每晚减少0.64次排尿(95%CI -0.98至-0.31,P<0.001),Qmax平均额外增加2.75 mL/s(95%CI 0.57至4.93,P=0.01)。
  • 与α受体阻滞剂相比,HESr在IPSS改善上相似(WMD 0.57,95%CI -0.27至1.42,P=0.18),Qmax改善与坦索罗辛相当(WMD -0.02,95%CI -0.71至0.66,P=0.95)。
  • 治疗6个月后,HESr与5α还原酶抑制剂(5ARIs)在IPSS评估的疗效上相似。
  • 全部已发表数据显示,HESr使IPSS较基线平均改善-5.73分(95%CI -6.91至-4.54,P<0.001)。
  • HESr未对性功能产生负面影响,对前列腺特异性抗原未见有临床相关的影响,前列腺体积略有减小。

临床怎么用

  • 对于寻求药物治疗的LUTS/BPH患者,HESr可作为改善夜尿和Qmax的选项。
  • 与α受体阻滞剂疗效相近且不影响性功能,可用于关注性功能副作用的患者。
  • 长期治疗(≥1年)疗效结果相似,安全性良好,可考虑长期使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To comprehensively evaluate the efficacy and safety of the hexanic extract of Serenoa repens (HESr, Permixon® ; Pierre Fabre Médicament, Castres, France), at a dose of 320 mg daily, as monotherapy for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). MATERIALS AND METHODS: We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) and prospective observational studies in patients with LUTS/BPH identified through searches in Medline, Web of Knowledge (Institute for Scientific Information), Scopus, the Cochrane Library, and bibliographic references up to March 2017. Articles studying S. repens extracts other than Permixon were excluded. Data were collected on International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax ), nocturia, quality of life, prostate volume, sexual function, and adverse drug reactions (ADRs). Data obtained from RCTs and observational studies were analysed jointly and separately using a random effects model. A sub-group analysis was performed of studies that included patients on longer-term treatment (≥1 year). RESULTS: Data from 27 studies (15 RCTs and 12 observational studies) were included for meta-analysis (total N = 5 800). Compared with placebo, the HESr was associated with 0.64 (95% confidence interval [CI] -0.98 to -0.31) fewer voids/night (P < 0.001) and an additional mean increase in Qmax of 2.75 mL/s (95% CI 0.57 to 4.93; P = 0.01). When compared with α-blockers, the HESr showed similar improvements on IPSS (weighted mean difference [WMD] 0.57, 95% CI -0.27 to 1.42; P = 0.18) and a comparable increase in Qmax to tamsulosin (WMD -0.02, 95% CI -0.71 to 0.66; P = 0.95). Efficacy assessed using the IPSS was similar after 6 months of treatment between the HESr and 5α-reductase inhibitors (5ARIs). Analysis of all available published data for the HESr showed a mean improvement in IPSS from baseline of -5.73 points (95% CI -6.91 to -4.54; P < 0.001). HESr did not negatively affect sexual function and no clinically relevant effect was observed on prostate-specific antigen. Prostate volume decreased slightly. Similar efficacy results were seen in patients treated for ≥1 year (n = 447). The HESr had a favourable safety profile, with gastrointestinal disorders being the most frequent ADR (mean incidence of 3.8%). CONCLUSION: The present meta-analysis, which includes all available RCTs and observational studies, shows that the HESr (Permixon) reduced nocturia and improved Qmax compared with placebo and had a similar efficacy to tamsulosin and short-term 5-ARI in relieving LUTS. HESr (Permixon) appears to be an efficacious and well-tolerated therapeutic option for the long-term medical treatment of LUTS/BPH.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018. PMID: 29694707. doi:10.1111/bju.14362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。